US · MGNX · BIOTECHNOLOGY
MacroGenics, Inc. (MGNX) intrinsic value and stock valuation
$1.96as of 2026-11-21 · Mkt cap 247.9M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
MacroGenics, Inc. DCF and intrinsic value
InvestorsCraft values MGNX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from MGNX’s statements →
MacroGenics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $149.5M | $148.3M | $57.2M | $150M | $75.6M |
| Operating income | -$-72.84M | -$-110.58M | -$-168.24M | -$-121.42M | -$-202.79M |
| Net income | -$-74.62M | -$-66.97M | -$-9.06M | -$-119.76M | -$-202.12M |
| EPSd | -$-1.18M | -$-1.07M | -$-146.29K | -$-1.95M | -$-3.37M |
| Operating cash flow | -$-81.04M | -$-68.37M | -$-78.2M | -$-86.96M | -$-143.83M |
| Capital expenditure | -$-1.91M | -$-3.71M | -$-1.76M | -$-3.62M | -$-6.2M |
| Free cash flow | -$-82.95M | -$-72.08M | -$-79.97M | -$-90.58M | -$-150.03M |
| Total assets | $256.9M | $261.7M | $298.4M | $289.5M | $335.3M |
| Total debt | $106.8M | $37.5M | $34M | $34.8M | $25.5M |
| Net debt | $49.6M | -$-145.38M | -$-66.98M | -$-74.05M | -$-98M |
| Total equity | $55.6M | $116.1M | $152.6M | $142M | $239.6M |
| Cash and short-term investments | $189.9M | $201.7M | $229.8M | $154.4M | $243.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $149.5M | $148.3M | $57.2M | $150M | $75.6M |
| Cost of revenue | $43.2M | $12.3M | $8.22M | $7.38M | $2.65M |
| Gross profit | $106.3M | $136M | $49M | $142.6M | $73M |
| Research and development expenses | $140M | $177.2M | $166.6M | $207M | $214.6M |
| Selling, general and administrative expenses | $39.2M | $71.1M | $52.2M | $59M | $63M |
| Other expenses | $0.00 | -$-1.62M | -$-1.56M | -$-1.92M | -$-1.8M |
| Operating expenses | $179.2M | $246.6M | $217.2M | $264.1M | $275.8M |
| Cost and expenses | $222.3M | $258.9M | $225.4M | $271.4M | $278.4M |
| Interest income | $3.4M | $9.42M | $9.69M | $1.7M | $680K |
| Interest expense | $8.51M | $1.11M | $1.43M | $0.00 | $0.00 |
| Depreciation and amortization | $7.17M | $7.54M | $9.64M | $11.9M | $11.3M |
| Ebitda | -$-59.61M | -$-57.37M | $2.02M | -$-107.89M | -$-190.86M |
| Operating income | -$-72.84M | -$-110.58M | -$-168.24M | -$-121.42M | -$-202.79M |
| Total other income/expenses, net | -$-2.45M | $44.6M | $159.2M | $1.66M | $680K |
| Income before tax | -$-75.29M | -$-66.02M | -$-9.06M | -$-119.76M | -$-202.12M |
| Income tax expense | -$-670K | $940K | $0.00 | $0.00 | $0.00 |
| Net income | -$-74.62M | -$-66.97M | -$-9.06M | -$-119.76M | -$-202.12M |
| Weighted average shares outstanding | $63.2M | $62.6M | $61.9M | $61.4M | $59.9M |
| Weighted average diluted shares outstanding | $63.2M | $62.6M | $61.9M | $61.4M | $59.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $189.9M | $201.7M | $229.8M | $154.4M | $243.6M |
| Net receivables | $13.4M | $4.31M | $10.4M | $56.2M | $10.4M |
| Inventory | $7.91M | $0.00 | $1.22M | $1.45M | $4.39M |
| Total current assets | $219.9M | $217.5M | $251.3M | $222.2M | $279.6M |
| Property, plant and equipment, net | $35.5M | $42.6M | $45.7M | $56.9M | $54.3M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $36.9M | $53.1M | $47.1M | $67.3M | $55.7M |
| Total assets | $256.9M | $261.7M | $298.4M | $289.5M | $335.3M |
| Accounts payable | $4.79M | $5.01M | $6.44M | $4.9M | $15.5M |
| Short-term debt | $5.18M | $4.86M | $3.77M | $4.73M | $4.68M |
| Deferred revenue | $10.9M | $16.3M | $21.7M | $9.99M | $0.00 |
| Total current liabilities | $43.1M | $55.5M | $56.1M | $48.6M | $74.6M |
| Long-term debt | $101.6M | $32.6M | $30.2M | $30.1M | $20.8M |
| Deferred revenue, non-current | $55.5M | $55.5M | $59.2M | $59.5M | $0.00 |
| Total non-current liabilities | $158.1M | $99M | $89.7M | $98.9M | $21.1M |
| Capital lease obligations | $31.6M | $37.5M | $34M | $30.1M | $25.5M |
| Total liabilities | $201.3M | $145.6M | $145.8M | $147.5M | $95.6M |
| Common stock | $630K | $630K | $620K | $620K | $610K |
| Retained earnings | -$-1.24B | -$-1.17B | -$-1.1B | -$-1.09B | -$-973.94M |
| Accumulated other comprehensive income (loss) | $30K | $0.00 | -$-10K | -$-10K | -$-60K |
| Total equity | $55.6M | $116.1M | $152.6M | $142M | $239.6M |
| Total investments | $132.7M | $18.8M | $128.9M | $45.5M | $120.2M |
| Total debt | $106.8M | $37.5M | $34M | $34.8M | $25.5M |
| Net debt | $49.6M | -$-145.38M | -$-66.98M | -$-74.05M | -$-98M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-74.62M | -$-66.97M | -$-9.06M | -$-119.76M | -$-202.12M |
| Depreciation and amortization | $5.52M | $7.54M | $9.64M | $11.9M | $11.3M |
| Stock-based compensation | $14.3M | $29.4M | $18.4M | $20.4M | $23.1M |
| Change in working capital | -$-28.33M | $1.39M | $53.3M | -$-6.13M | $17.6M |
| Accounts receivable | -$-9.06M | $6.06M | $45.9M | -$-45.84M | $12.7M |
| Inventory | -$-7.91M | -$-2.19M | $230K | $60K | -$-6.42M |
| Accounts payable | -$-280K | -$-1.53M | $1.28M | -$-10.86M | $7.12M |
| Net cash provided by operating activities | -$-81.04M | -$-68.37M | -$-78.2M | -$-86.96M | -$-143.83M |
| Investments in property, plant and equipment | -$-1.91M | -$-3.71M | -$-1.76M | -$-3.62M | -$-6.2M |
| Acquisitions, net | $10K | $0.00 | $60K | $0.00 | $0.00 |
| Net cash used for investing activities | -$-114.1M | $149.3M | -$-80.08M | $70.7M | -$-36.61M |
| Common stock issued | $130K | $3.44M | $1.17M | $1.08M | $117.8M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $69.5M | $960K | $150.4M | $1.66M | $122.8M |
| Net change in cash | -$-125.62M | $81.9M | -$-7.93M | -$-14.59M | -$-57.66M |
| Cash at end of period | $57.2M | $182.8M | $101M | $108.9M | $123.5M |
| Operating cash flow | -$-81.04M | -$-68.37M | -$-78.2M | -$-86.96M | -$-143.83M |
| Capital expenditure | -$-1.91M | -$-3.71M | -$-1.76M | -$-3.62M | -$-6.2M |
| Free cash flow | -$-82.95M | -$-72.08M | -$-79.97M | -$-90.58M | -$-150.03M |
Line items
Line items
Line items
About MacroGenics, Inc.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
- CEO
- Eric Risser
- Employees
- 293
- Beta
- 1.18
Explore
Frequently asked questions
What is the intrinsic value of MacroGenics, Inc. (MGNX)?
MacroGenics, Inc. (MGNX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is MGNX undervalued?
MGNX trades at a price of $1.96 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.